US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

35.81

-0.4800-1.32%

Post-market: 35.810.00000.00%19:57 EDT

Volume:400.39K

Turnover:14.39M

Market Cap:425.42M

PE:- -

High:36.29

Open:36.16

Low:35.72

Close:36.29

52wk High:39.39

52wk Low:25.85

Shares:11.88M

Float Shares:11.88M

Volume Ratio:2.13

T/O Rate:3.37%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Competition Intensifies in Second-Line EGFR 20ins NSCLC Treatment: Can Fumeitinib Challenge Sunvozertinib's Dominance?

Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":35.81,"timestamp":1774641600000,"preClose":36.29,"halted":0,"volume":400387,"hourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01322678423808203,"floatShares":11880000,"shares":11880000,"eps":0,"marketStatus":"Market Closed","change":-0.48,"latestTime":"03-27 16:00:00 EDT","open":36.16,"high":36.29,"low":35.72,"amount":14394852.358289002,"amplitude":0.015707,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":36.29,"sharesOutstanding":12900000,"nav":36.65,"aum":435402000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":36.18,"preClose":36.29,"latestTime":"09:19 EDT","volume":11,"amount":397.98,"timestamp":1774617580197,"change":-0.11,"changeRate":-0.003031,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.12915,"impliedVol":0.0274,"impliedVolPercentile":0.0357},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":11880000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.12915,"shares":11880000,"dividePrice":0,"high":36.29,"amplitude":0.015707,"preClose":36.29,"low":35.72,"week52Low":25.85,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":35.81,"eps":0,"divideRate":0,"volume":400387,"delay":0,"ttmEps":0,"open":36.16,"prevYearClose":34.16,"prevWeekClose":35.79,"prevMonthClose":39.08,"prevQuarterClose":34.16,"fiveDayClose":35.79,"twentyDayClose":39.08,"sixtyDayClose":34.345},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622237908","title":"Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622237908","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622237908?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:00","pubTimestamp":1774609200,"startTime":"0","endTime":"0","summary":"AUCATZYL (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL UK launch underway following successful Nat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3263674/0/en/Autolus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","BK4230","CAR","LU0985320562.USD","LU2065731478.USD","IE0031619046.USD","LENZ","BK4007","CRS","BK4109","BK4533","BK4110","BK4566","BK4139","IE00B19Z4B17.USD","ORR","BK4023","LU1699723380.USD","IE00B7SZL793.SGD","LU2355687059.USD","ALL","BK4107","NICE","BK4006","BK4543","ASH","ACR","BK4187","IE00B66KJ199.SGD","LU2463526074.USD","BK4022","BK4588","BK4539","LU1571399168.USD","IE00BFMHRM44.USD","BK4585"],"gpt_icon":0},{"id":"1103719113","title":"Competition Intensifies in Second-Line EGFR 20ins NSCLC Treatment: Can Fumeitinib Challenge Sunvozertinib's Dominance?","url":"https://stock-news.laohu8.com/highlight/detail?id=1103719113","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103719113?lang=en_us&edition=fundamental","pubTime":"2026-03-27 16:00","pubTimestamp":1774598456,"startTime":"0","endTime":"0","summary":"The recommendation levels in the CSCO (Chinese Society of Clinical Oncology) guidelines serve as a bridge connecting high-level medical evidence with complex clinical decisions. These levels are not...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","OS","BK4097"],"gpt_icon":0},{"id":"2622247863","title":"Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2622247863","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622247863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531920,"startTime":"0","endTime":"0","summary":"-- The global, multicenter Phase I/II clinical trial of CS2009. Australia and China, and the Phase II IND application has been approved. in the US. CS2009 demonstrates an excellent safety profile with a >=Grade. 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity.Notably, monotherapy data in lung cancer are encouraging: in first-line. NSCLC patients with PD-L1 TPS >=50%, the ORR reached 90% with a DCR of. 100%, while the ORR was 25% in IO-pretreated NSCLC .Furthermore, significant benefits were observed in patients with heavily. pre-treated \"cold tumors,\" achieving an ORR of 40% in non-clear cell. renal cell carcinoma  and 33.3% in soft tissue sarcoma .-- The global Phase Ib multicenter trial of CS5001  is being. advanced rapidly and efficiently in Australia and China, with its R&D. progress ranking among the top two globally. In combination with R-CHOP. rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination. complementing its successful NRDL renewal at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1721428933.USD","MTD","BK4107","BK4006","BK4585","BK4232","BK4533","BK4213","LU0456854461.SGD","LU0266512127.USD","LU2211817866.USD","PROC","LU2413666699.HKD","LU0347712357.USD","PD","LU1093756168.USD","BK1574","HCC","BK4121","L","LU1169590202.USD","BK4022","BK4567","LU0053666078.USD","PK","IE00BFXG0V08.USD","BK4548","LU2487616109.SGD","BK4218","IE00BYQQ9H92.USD","BK4588","BK4181","CRC","LU0210528500.USD","02616","ORR","BK4098","BK4023","IE00B5TLWC47.USD","LU1169589451.USD","BK1161","BK4156","R","LU1093756325.SGD","CC","LU2413666426.HKD"],"gpt_icon":0},{"id":"2622852318","title":"Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852318","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852318?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"200g Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin CancerPHILADELPHIA, March  26, 2026 (GLOBE NEWSWI","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4213","MNA","AIPO","MDCX","BK4215","BK4161","BK4104","LU1169590202.USD","CSR","CR","BK4567","BCC","ORR","CHAT","PR","PD","BK4023","AGIX","LU1169589451.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":35,"pageCount":1,"totalSize":140,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}